Heads Up: MAIA Biotechnology (NYSE: MAIA) Just Hit Our Radar This Morning

*Sponsored After His Last Two Biotechs Combine For Approx. 133% Moves, Jeff Ackerman Launches Full Coverage On MAIA Biotechnology (NYSE: MAIA) MAIA Biotechnology (NYSE: MAIA) Is Topping Our Watchlist  This Morning—Friday, May 2, 2025 And Here’s Why… Analyst Robert LeBoyer Set A $14 Target On (MAIA), Indicating Over 500% Potential Upside From Recent Levels. (MAIA) Has Moved Approximately 85% In The Past Month, From $1.40 On April 10 To $2.60 Yesterday. The Company Holds Multiple FDA Designations, Including Priority Review Vouchers And Multi-Year Regulatory Exclusivity. Active Trials Are Underway In Colorectal, Liver, And Small Cell Lung Cancers, Adding To Its Lead Program In NSCLC. Pull Up (MAIA) This Morning While It’s Still Early… May 2, 2025 Dear Reader, If you've been following our recent Biotech coverage, you've likely noticed the momentum building. Our featured profile from Wednesday night made an approximate 91% overnight move yesterday.  Just one night earlier—Tuesday’s Biotech profile—showcased an approximate 42% move overnight into Wednesday’s session. Now, we’re setting our sights on what comes next. And that next profile is MAIA Biotechnology (NYSE: MAIA). For those of you subscribed to our Desktop Push Notifications, you might recognize this name from Tuesday, April 22, when it quietly closed at $1.87. Yesterday? It touched $2.60, showcasing an approximate 39% move in just a week and a half. That kind of setup, paired with what we’re about to show you, is why MAIA is now getting our full attention—and why it’s topping our watchlist heading into tomorrow morning. We have all eyes on (MAIA) this morning—here’s why. Technical Moves & Analyst Firepower… In just the past month, (MAIA) has quietly moved approximately 85%, from $1.40 on April 10 to $2.60 yesterday—surpassing all major moving averages tracked by Barchart. One analyst, Robert LeBoyer, Senior Vice President of Equity Research in Biotechnology, recently set a $14 target on (MAIA). That figure suggests more than 500% upside potential from its recent $2.32 range. But the charts and commentary only hint at what’s underneath this move. Because this isn’t just a story about momentum. It’s about a different way to fight cancer. The Little-Known Biotech You’re About to Hear More Of… Here’s why (MAIA)’s story is now being tracked far more closely by industry watchers and market analysts alike: Survival That Defies Expectations: (MAIA)’s lead molecule, THIO (ateganosine), has delivered a median overall survival of 16.9 months in third-line NSCLC patients who had already failed both chemotherapy and checkpoint inhibitors. Standard therapies in this group typically offer just 5 to 6 months of survival. Partnered With a Powerhouse: (MAIA)’s Phase 2 THIO-101 trial is conducted in combination with Libtayo®, Regeneron’s checkpoint inhibitor. Rather than competing with leading immunotherapies, MAIA’s molecule appears to unlock their full effect in resistant tumors. Positioned in the Largest Cancer Market: NSCLC remains the #1 tumor type globally by sales, generating $34B annually. THIO is designed for a treatment setting—third-line patients—where no approved telomere-targeting agents exist and options remain limited. Platform Expansion Already in Motion: Beyond lung cancer, (MAIA) is preparing new trials in colorectal cancer, liver cancer, and small cell lung cancer—all high-mortality conditions where checkpoint inhibitors alone have struggled to deliver consistent results. A Head Start Few Can Match: THIO holds three FDA Orphan Designations (for HCC, SCLC, and glioblastoma) and a Rare Pediatric Disease Designation for high-grade gliomas. These designations create long-term protection—and access to priority review vouchers historically valued up to $100M. Behind the Scenes: Inside the Execution… CEO Dr. Vlad Vitoc has spent decades in oncology—helping lead the commercial success of therapies like Nexavar, Tarceva, and Xtandi at companies like Bayer and Astellas. On (MAIA)’s most recent update, he made something clear: this isn’t just a moonshot—it’s an execution plan. The company expects to launch its THIO-104 Phase 3 pivotal trial in mid-2025—directly comparing THIO + CPI versus chemotherapy in third-line NSCLC. That trial isn’t just about validation. If interim results align with current data, it could lay the foundation for early full FDA approval as soon as 2026. Meanwhile, second-generation telomere-targeting molecules are already moving through preclinical development, backed by intellectual property protections extending through 2041 and beyond. The Strategic Shift Is Clear… What began as a targeted clinical experiment has grown into a multi-indication oncology platform. In preclinical models, THIO + checkpoint inhibitor combinations have shown not only complete tumor regression, but also no recurrence—even after being rechallenged with cancer cells. The reason?  Immune memory. The immune system isn’t just attacking cancer. It’s learning how to recognize it. That immune effect has now been observed across colorectal, liver, and small cell lung cancer models—all of which are being advanced toward human trials. By now, it’s clear that (MAIA) isn’t chasing short-term signals—it’s building something much broader. A Closer Look at the Pipeline… (MAIA)’s pipeline isn’t limited to a single trial or indication—it’s a strategically layered clinical program spanning multiple tumor types and stages.  The company is currently initiating its Phase 3 THIO-104 trial in third-line NSCLC in combination with Libtayo®, while continuing its Phase 2 THIO-101 trial in second-line NSCLC.  Three additional Phase 2 trials—THIO-102-CRC, THIO-102-HCC, and THIO-102-SCLC—are planned to evaluate ateganosine alongside tislelizumab in colorectal, liver, and small cell lung cancers, respectively. A Phase 2/3 trial (THIO-103) is also in development for first-line treatment in both NSCLC and SCLC.  Beyond these, (MAIA) is advancing preclinical, IND-enabling programs like MAIA-2021-020, focused on additional tumor types.  All programs are fully owned by the company and designed to build out a comprehensive telomere-targeting immunotherapy platform. It’s not often you see a little-known company managing this level of clinical complexity—let alone doing it with full ownership across the board. That’s one of many reasons why (MAIA) has rapidly climbed the ranks on our radar this week. 5 Reasons Why MAIA Biotechnology (NYSE: MAIA) is Topping Our Watchlist This Morning—Friday, May 2, 2025… 1. Analyst Target Spotlight: Analyst Robert LeBoyer recently issued a $14 target on (MAIA), suggesting over 500% upside potential from recent levels. 2. Strong Technical Momentum: (MAIA) has moved approximately 124% in the last month, climbing from $1.40 on April 10 to $2.47 today. 3. Regulatory Advantage: (MAIA) holds multiple FDA designations, providing access to priority review vouchers and multi-year regulatory exclusivity. 4. Pipeline Expansion Underway: (MAIA) is advancing trials across colorectal, liver, and small cell lung cancers, expanding beyond its lead indication. 5. Proven Leadership Track Record: (MAIA)’s leadership team includes executives who helped bring Xtandi, Tarceva, and Nexavar to market. These aren’t just scattered highlights—they’re converging signals that demand attention. When you see a name check this many boxes, it’s not one to overlook heading into a Friday open. Momentum like this doesn’t usually wait around—and neither should you. Why You Should Pull Up (MAIA) This Morning—Friday, May 2, 2025… (While It’s Still Early) With momentum accelerating, clinical progress unfolding, and analyst attention now focused, MAIA Biotechnology (NYSE: MAIA) is stepping into the spotlight at a time when very few names are showing this kind of convergence. The combination of technical strength, regulatory positioning, and experienced leadership is why this name has moved to the top of our watchlist heading into this morning. We have all eyes on (MAIA) this morning. Pull up (MAIA) while it’s still early. Also, keep an eye out for my next update—it should be out to you very shortly. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 05/02/2025 and ending on 05/02/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, TD Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid three hundred eighty seven thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (MAIA:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/maia-kj7gc/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice